Abbott Wins European Approval for Latest MitraClip Heart Valve Device

Abbott Wins European Approval for Latest MitraClip Heart Valve Device

Abbott Laboratories (NYSE: ABT) has scored a fresh victory across the Atlantic Ocean. The company announced Monday that it has been granted a CE Mark for its MitraClip G4, the latest version of its popular heart valve replacement device, which means it is approved for use in the countries of the European Union. The G4 had already been approved for use in the U.S. by the Food and Drug Administration.